Oxford Molecular Group PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford Molecular Group PLC
By combining quantum chemistry and computing power, QuantumBio Inc. says it can model large macromolecules far better and more efficiently than currently available mechanics-based software. The company's tools promise better predictability of chemical and physical properties for virtual screening, QSAR, ADME/Tox, lead optimization and docking.
IP2IPO Ltd. aims to facilitate technology transfer from UK universities, securing funding and advice to help commercialize intellectual property (IP).
Oxford University's technology transfer group, Isis Innovation, has been around for thirteen years. But it's only since 1997 that the show has really begun.
Current in vivo and in vitro models can't keep up with the demand for the safety assessment of large numbers of compounds emerging from high-throughput strategies. Pharmaceutical companies and start-ups are therefore building new systems that they hope will be capable of predicting the toxicity liabilities of new compounds. Cheminformatics can help week out toxic compounds at the lead selection and optimization stage; toxicogenomics may provide a toxicity diagnostic capability at all stages of drug development. For both toxicology approaches, there is not yet enough high quality data to build predictive models. Toxicology-focused cheminformatics programs attempt to consolidate data from hitherto untapped sources; toxicogenomics companies are engaged in the fussy and expensive process of manufacturing data from scratch and validating them with biological experiments.
- Other Names / Subsidiaries
- Chemical Design Holdings PLC